Byondis Seeks Partner For Lead ADC To Enter Crowded Breast Cancer Market
Positive Top-Line Results From TULIP Study
Executive Summary
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.
You may also be interested in...
MacroGenics Gets Nod For Margenza In HER2-Positive Breast Cancer
The drug may see a muted launch given the competitive landscape and a broad label despite its efficacy advantage in F-allele patients.
Pipeline Watch: The Bumper ASCO Edition
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
European Biotech: Innovation Hotspots To Drive Growth
Europe’s strengths in the biotech space include world-class science, but the continent needs to build on its strengths in order to deliver on the promise of a coming “golden age” of biotech, says a recent report.